Levobunolol

Levobunolol
Clinical data
Trade names	Betagan
AHFS/Drugs.com	Monograph
MedlinePlus	a686011
Pregnancy; category	C;
Routes of; administration	Topical (eye drops)
ATC code	S01ED03 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	20 hours
Identifiers
	IUPAC name (S)-5-{[3-(tert-Butylamino)-2-hydroxypropyl]oxy}-3,4-dihydronaphthalen-1(2H)-one;
CAS Number	47141-42-4 ;
PubChem CID	39468;
IUPHAR/BPS	570;
DrugBank	DB01210 ;
ChemSpider	36089 ;
UNII	G6317AOI7K;
KEGG	D08115 ;
ChEBI	CHEBI:6438 ;
ChEMBL	ChEMBL1201237 ;
CompTox Dashboard (EPA)	DTXSID1043833 ;
Chemical and physical data
Formula	C17H25NO3
Molar mass	291.385 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2c1cccc(OC[C@@H](O)CNC(C)(C)C)c1CCC2;
	InChI InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1 ; Key:IXHBTMCLRNMKHZ-LBPRGKRZSA-N ;
	(what is this?) (verify)

Levobunolol (AK-Beta, Liquifilm, Betegan) is a non-selective beta blocker. It is used topically to manage glaucoma.

References

Ishibashi T, Yokoi N, Kinoshita S (2003). "Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface". Cornea. 22 (8): 709–15. doi:10.1097/00003226-200311000-00001. PMID 14576520.
Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S (1999). "[Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]". Nippon Ganka Gakkai Zasshi. 103 (7): 544–50. PMID 10443129.
Leung M, Grunwald J (1997). "Short-term effects of topical levobunolol on the human retinal circulation". Eye. 11 (3): 371–6. doi:10.1038/eye.1997.78. PMID 9373479.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.